Skip to Content
Merck
  • Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

World journal of gastroenterology (2014-12-04)
Mattheus C B Wielenga, Jooske F van Lidth de Jeude, Sanne L Rosekrans, Alon D Levin, Monique Schukking, Geert R A M D'Haens, Jarom Heijmans, Marnix Jansen, Vanesa Muncan, Gijs R van den Brink
ABSTRACT

To investigate if azathioprine could reduce adenoma formation in Apc(Min/+) , a mouse model of sporadic intestinal tumorigenesis. Azathioprine was administered via drinking water (estimated 6-20 mg/kg body weight per day) to Apc(Min/+) and wildtype mice. Control animals received vehicle only (DMSO) dissolved in drinking water. At 15 wk of age all mice were sacrificed and intestines of Apc(Min/+) were harvested for evaluation of polyp number. Azathioprine induced toxicity was investigated by immunohistochemical analysis on spleens. All azathioprine treated mice showed signs of drug-associated toxicity such as weight loss and development of splenic T-cell lymphomas. Although this suggests that the thiopurine concentration was clearly in the therapeutic range, it did not reduce tumor formation (48 ± 3.1 adenomas vs 59 ± 5.7 adenomas, P = 0.148). We conclude that in the absence of inflammation, azathioprine does not affect intestinal tumorigenesis.

MATERIALS
Product Number
Brand
Product Description

USP
Azathioprine, United States Pharmacopeia (USP) Reference Standard
Azathioprine, European Pharmacopoeia (EP) Reference Standard
Supelco
Azathioprine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Azathioprine, ≥98%